NBIX
NASDAQNeurocrine Biosciences Inc.
Price$130.22-1.72 (-1.30%)
01:30 PM07:45 PM
News · 26 weeks690%
2025-10-262026-04-19
Mix4090d
- Insider22(55%)
- Other8(20%)
- SEC Filings5(13%)
- Earnings3(8%)
- Analyst1(3%)
- Leadership1(3%)
Latest news
25 items- PRNeurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal HyperplasiaApproximately 70% of adult patients treated with CRENESSITY achieved and sustained physiologic‑range glucocorticoid dosing at two years75% of patients originally taking dexamethasone transitioned off this treatment, enabling a more physiologic glucocorticoid regimen without compromising androgen controlFindings reinforce durable efficacy and a favorable long‑term safety profile in largest interventional trial to date conducted in classic congenital adrenal hyperplasiaSAN DIEGO, April 22, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the first presentation of new two-year data from the Phase 3 CAHtalyst® Adult study demonstrating sustained, substantial reduct
- SECSEC Form DEFA14A filed by Neurocrine Biosciences Inc.DEFA14A - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
- SECSEC Form DEF 14A filed by Neurocrine Biosciences Inc.DEF 14A - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
- PRNeurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial ResultsConference Call and Webcast Scheduled for Tuesday, May 5SAN DIEGO, April 14, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its first quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on May 5, 2026. The schedule for the press release and conference call / webcast is as follows:Q1 2026 Press Release: May 5, 2026 at 1:00 p.m. PT / 4:00 p.m. ETQ1 2026 Conference Call: May 5, 2026 at 1:30 p.m. PT / 4:30 p.m. ETDomestic Dial-In Number: 800-274-8461International Dial-In
- PRNeurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XRINGREZZA showed higher rates of long-term treatment continuation and lower switching between medications compared to AUSTEDO XR (deutetrabenazine) in a real-world claims analysis among adults with tardive dyskinesiaHigher continuation with INGREZZA was observed early in treatment and persisted across a six‑month follow‑up periodSAN DIEGO, April 14, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new real-world evidence demonstrating that adult patients with tardive dyskinesia receiving INGREZZA® (valbenazine) capsules showed higher treatment persistence compared to those on AUSTEDO XR (deutetrabenazine). The findings are being presented at
- SECNeurocrine Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
- PRNeurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease PortfolioVYKAT™ XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and Represents a Transformative Therapy Expands Neurocrine's High-Growth Commercial Portfolio to Three First-in-Class Medicines Including INGREZZA® (valbenazine) and CRENESSITY® (crinecerfont)Establishes a Durable Platform for Long-Term Revenue Growth and Value Creation, Supported by Strong VYKAT XR Intellectual Property Estate Expected to Extend into the mid-2040sNeurocrine to Host Conference Call at 8:00 AM ET Today to Discuss Transaction SAN DIEGO and REDWOOD CITY, Calif., April 6, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) and Soleno Therapeutics, Inc.
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Neurocrine Biosciences Inc.SCHEDULE 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
- PRNeurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care SettingsExpert panel establishes structured approach to tardive dyskinesia screening, diagnosis and treatment in long-term care, including use of VMAT2 inhibitorsNew post-hoc KINECT‑PRO™ analysis in adults aged 65 years and older demonstrates clinically meaningful patient-reported improvements in tardive dyskinesia impact with INGREZZA® (valbenazine) capsules, reinforcing expert panel recommendationsSAN DIEGO, March 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of the first expert consensus recommendations focused on screening, diagnosis and treatment of tardive dyskinesia among older adults in long-term care settings. Developed through a multi
- INSIDERNew insider Ratz Andrew claimed ownership of 1,018 shares (SEC Form 3)3 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- PRNeurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations OfficerSAN DIEGO, March 17, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the promotion of Andrew Ratz, Ph.D., to the executive management team as the Chief Technical Operations Officer. In his new role, Dr. Ratz will lead the company's global technical development, manufacturing, and supply chain functions, supporting Neurocrine's expansion beyond small molecules into biologics and device-based therapies. Dr. Ratz – who joined Neurocrine in January 2025 as Senior Vice President of Drug Development, Delivery and Device – previously spent nearly 30 year
- PRNeurocrine Biosciences to Present at the Stifel 2026 Virtual CNS ForumSAN DIEGO, March 10, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that members of the management team will participate at the Stifel 2026 Virtual CNS Forum at 4:30 PM EST on March 17, 2026. The live webcast can be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.About Neurocrine BiosciencesNeurocrine Biosciences is a leading biopharmaceutical company
- PRBetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX)TROY, Mich., March 6, 2026 /PRNewswire/ -- Equifax Inc.'s recent report has investors wondering if the company's stock is fairly valued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine considers Equifax (NYSE:EFX) as worthy of further study and has named the company its "Stock to Study" for the May 2026 issue for investors' informational and educational use. The fundamental data is eye-opening; investors can view Equifax's sales, earnings, pre-tax profit, return on equity, and more all on one page, courtesy of the National Association of Investors Corp., at: https://ssg.betterinvesting.org/trial/ssgplus/?ticker=EFX.A full
- INSIDERChief Financial Officer Abernethy Matt gifted 2,249 shares, decreasing direct ownership by 5% to 42,808 units (SEC Form 4)4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- PRNeurocrine Biosciences to Present at Upcoming Investor Conferences in MarchSAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that members of the management team will participate at the following investor conferences: TD Cowen 46th Annual Health Care Conference. Fireside chat on Tuesday, March 3, 2026 at 11:50 AM ET in BostonLeerink Global Healthcare Conference. Fireside chat on Monday, March 9, 2026 at 8:40 AM ET in MiamiThe live webcasts can be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcasts will be available on the website approximately one h
- ANALYSTWolfe Research initiated coverage on Neurocrine Biosciences with a new price targetWolfe Research initiated coverage of Neurocrine Biosciences with a rating of Outperform and set a new price target of $160.00
- INSIDERChief Scientific Officer Onyia Jude gifted 3,110 shares, decreasing direct ownership by 11% to 25,670 units (SEC Form 4)4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- INSIDERChief Financial Officer Abernethy Matt converted options into 6,940 shares, covered exercise/tax liability with 9,124 shares and was granted 9,968 shares, increasing direct ownership by 21% to 44,881 units (SEC Form 4)4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- INSIDERChief Corp. Affairs Officer Boyer David W. covered exercise/tax liability with 8,052 shares, was granted 9,968 shares and converted options into 4,952 shares, increasing direct ownership by 146% to 11,581 units (SEC Form 4)4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- INSIDERChief Executive Officer Gano Kyle converted options into 9,714 shares, covered exercise/tax liability with 10,621 shares and was granted 9,968 shares, increasing direct ownership by 6% to 150,815 units (SEC Form 4)4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- INSIDERChief Scientific Officer Onyia Jude was granted 19,935 shares, converted options into 7,967 shares and covered exercise/tax liability with 15,099 shares, increasing direct ownership by 80% to 28,780 units (SEC Form 4)4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- INSIDERChief Commercial Officer Benevich Eric converted options into 6,049 shares, covered exercise/tax liability with 12,227 shares and was granted 16,613 shares, increasing direct ownership by 20% to 63,190 units (SEC Form 4)4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- INSIDERChief Human Resources Officer Cooke Julie was granted 9,968 shares, converted options into 4,298 shares and covered exercise/tax liability with 7,698 shares, increasing direct ownership by 24% to 34,170 units (SEC Form 4)4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- INSIDERChief Legal Officer Lippoldt Darin converted options into 5,892 shares, covered exercise/tax liability with 8,558 shares, was granted 9,968 shares and gifted 365 shares, increasing direct ownership by 15% to 54,729 units (SEC Form 4)4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- INSIDERChief Regulatory Officer Delaet Ingrid covered exercise/tax liability with 13,126 shares, was granted 19,935 shares and converted options into 4,360 shares, increasing direct ownership by 221% to 16,225 units (SEC Form 4)4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)